Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lessened its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 13.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 711,521 shares of the biopharmaceutical company’s stock after selling 105,898 shares during the quarter. Fisher Asset Management LLC owned about 1.27% of Agios Pharmaceuticals worth $15,846,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Frazier Life Sciences Management L.P. grew its holdings in Agios Pharmaceuticals by 79.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 523,166 shares of the biopharmaceutical company’s stock valued at $11,651,000 after buying an additional 231,164 shares during the last quarter. Norges Bank acquired a new stake in Agios Pharmaceuticals during the 4th quarter valued at $6,826,000. Assenagon Asset Management S.A. boosted its holdings in shares of Agios Pharmaceuticals by 478.1% during the fourth quarter. Assenagon Asset Management S.A. now owns 50,504 shares of the biopharmaceutical company’s stock worth $1,125,000 after purchasing an additional 41,768 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $951,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Agios Pharmaceuticals by 3.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 451,695 shares of the biopharmaceutical company’s stock worth $11,179,000 after purchasing an additional 14,420 shares during the last quarter.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $42.56 on Wednesday. The business’s 50-day moving average is $35.97 and its two-hundred day moving average is $29.51. Agios Pharmaceuticals, Inc. has a 12 month low of $19.80 and a 12 month high of $49.06. The firm has a market capitalization of $2.42 billion, a PE ratio of -6.73 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, beating the consensus estimate of ($1.65) by $0.20. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The company had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. During the same period last year, the company posted ($1.47) earnings per share. The firm’s revenue was up 46.0% compared to the same quarter last year. Equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.57 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Royal Bank of Canada raised their price objective on Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an “outperform” rating in a report on Tuesday, June 4th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 29th. JPMorgan Chase & Co. restated a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Monday. Finally, The Goldman Sachs Group increased their target price on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 4th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Agios Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $50.67.

Insider Activity

In other news, Director Jacqualyn A. Fouse sold 7,791 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total transaction of $214,642.05. Following the completion of the sale, the director now directly owns 137,396 shares in the company, valued at $3,785,259.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.